Rhenman & Partners Asset Management AB Boosts Stock Position in Iovance Biotherapeutics, Inc. $IOVA

Posted by George Bondi on Jun 13th, 2026

Rhenman & Partners Asset Management AB lifted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Free Report) by 45.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 1,595,327 shares of the biotechnology company’s stock after purchasing an additional 497,500 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Iovance Biotherapeutics were worth $4,355,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. HRT Financial LP boosted its holdings in shares of Iovance Biotherapeutics by 1,078.3% in the 4th quarter. HRT Financial LP now owns 4,356,010 shares of the biotechnology company’s stock worth $11,891,000 after purchasing an additional 3,986,314 shares in the last quarter. DRW Securities LLC purchased a new position in shares of Iovance Biotherapeutics in the 4th quarter worth about $78,000. MetLife Investment Management LLC boosted its holdings in shares of Iovance Biotherapeutics by 20.5% in the 4th quarter. MetLife Investment Management LLC now owns 170,782 shares of the biotechnology company’s stock worth $466,000 after purchasing an additional 29,096 shares in the last quarter. Cibc World Markets Corp purchased a new position in shares of Iovance Biotherapeutics in the 4th quarter worth about $56,000. Finally, Renaissance Technologies LLC purchased a new position in shares of Iovance Biotherapeutics in the 4th quarter worth about $1,777,000. 77.03% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on IOVA shares. Citizens Jmp upgraded Iovance Biotherapeutics from a “market perform” rating to a “market outperform” rating and set a $5.00 price objective for the company in a report on Tuesday, March 3rd. Wall Street Zen upgraded Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. UBS Group upped their price objective on Iovance Biotherapeutics from $2.00 to $4.00 and gave the stock a “neutral” rating in a report on Thursday, March 5th. Truist Financial upgraded Iovance Biotherapeutics to a “hold” rating in a report on Wednesday, March 25th. Finally, Barclays increased their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.43.

View Our Latest Stock Report on Iovance Biotherapeutics

Iovance Biotherapeutics Price Performance

Shares of IOVA stock opened at $4.08 on Friday. The stock has a market capitalization of $1.82 billion, a PE ratio of -4.29 and a beta of 0.74. Iovance Biotherapeutics, Inc. has a 1-year low of $1.66 and a 1-year high of $5.63. The business has a 50-day moving average of $3.74 and a 200 day moving average of $3.23.

Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The company had revenue of $71.43 million during the quarter, compared to analysts’ expectations of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.Iovance Biotherapeutics’s quarterly revenue was up 44.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.36) EPS. Analysts anticipate that Iovance Biotherapeutics, Inc. will post -0.63 EPS for the current year.

Iovance Biotherapeutics Profile

(Free Report)

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.